Akılcı ilaç kullanımı: Yeni nesil oral antikoagülanlar
Öz
Anahtar Kelimeler
Kaynakça
- Hirsh J, Fuster V, Ansell J, Halperin JL; American Heart Association, American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107 (12): 1692-711.
- Trikha R, Kowey PR. Practical considerations for the nonvitamin K antagonist oral anticoagulants. Cardiology 2017; 136 (2): 115-24.
- Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol 2018; 15 (5): 273-81.
- Reddy ST, Cossey TC, Savitz SI, Grotta JC. Non-vitamin K oral anticoagulants (NOACs) and their reversal. Curr Neurol Neurosci Rep 2017; 17: 67.
- Barnes GD, Kurtz B. Direct oral anticoagulants: unique properties and practical approaches to management. Heart 2016; 102 (20): 1620-6.
- Verdecchia P, Angeli F, Aita A, Bartolini C, Reboldi G. Why switch from warfarin to NOACs? Intern Emerg Med 2016; 11 (3): 289-93.
- Abed HS, Kilborn MJ, Chen V, Sy RW. Reversal Agents in the Era of NOACs. J Atr Fibrillation 2017; 10 (4): 1634.
- Milling TJ Jr, Ziebell CM. A review of reversal of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery. Trends Cardiovasc Med 2019. pii: S1050-1738 (19) 30041-6.
Ayrıntılar
Birincil Dil
Türkçe
Konular
Sağlık Kurumları Yönetimi
Bölüm
Olgu Sunumu
Yazarlar
Nur Akad Soyer
0000-0002-7722-506X
Türkiye
Yayımlanma Tarihi
20 Ocak 2021
Gönderilme Tarihi
6 Nisan 2020
Kabul Tarihi
28 Ağustos 2020
Yayımlandığı Sayı
Yıl 2021